Drug or treatment

Zanubrutinib clinical trials

• 60Clinical trials
• 24Countries

Newest trials

All recruiting trials (60)

• Zanubrutinib plus Lenalidomide for frail elderly with newly diagnosed PCNSL

  This study tests whether a combination of zanubrutinib and lenalidomide can help frail elderly patients with newly diagnosed primary CNS lymphoma.

  Recruiting Phase 2 Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT07839247

• Venetoclax plus Zanubrutinib for CLL/SLL in frontline or previously treated patients

  This phase II trial tests if venetoclax plus zanubrutinib can safely and effectively treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma, including those who are newly diagnosed and those who have had prior therapy.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07734038

• MRD-guided Zanubrutinib + Sonrotoclax in new high-risk CLL/SLL

  This trial tests a time-limited, MRD-guided combination therapy with zanubrutinib and sonrotoclax for adults up to 75 with previously untreated high-risk CLL/SLL.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07671378

• Polatuzumab vedotin with Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in untreated DLBCL (MCD/BN2/N1)

  This study tests a targeted combination therapy to see if it can treat previously untreated DLBCL with specific molecular subtypes.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07608978

• Pola-ZR-Glo for older patients with large B‑cell lymphoma

  This trial will try combining polatuzumab vedotin, zanubrutinib, lenalidomide, and glofitamab as first-line treatment for people aged 70 and older with newly diagnosed large B‑cell lymphoma who are unfit for standard chemo or decline immunochemotherapy.

  Recruiting Phase 2 Ruijin Hospital · Shanghai · NCT07514169

• Zanubrutinib, rituximab, lenalidomide plus tislelizumab for relapsed/refractory follicular lymphoma

  This trial tests whether adding the PD‑1 blocker tislelizumab to zanubrutinib, rituximab, and lenalidomide helps adults with relapsed or refractory follicular lymphoma who have had at least two prior therapies.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07418190

• Zanubrutinib for anti‑MAG IgM‑associated demyelinating neuropathy

  This trial will try zanubrutinib, an oral BTK inhibitor, in adults with anti‑MAG IgM‑associated demyelinating neuropathy to see if 12 months of treatment improves nerve function and symptoms.

  Recruiting at 7 sites Phase 2 Azienda Ospedaliera di Padova · Milan, Milan and 6 other locations · NCT07392229

• Zanubrutinib plus Pola-R-CHP for newly diagnosed high-risk diffuse large B‑cell lymphoma

  This tests whether adding the BTK inhibitor zanubrutinib to a Pola-R-CHP regimen helps people with newly diagnosed DLBCL who have high-risk features.

  Recruiting Phase 2 Beijing Tongren Hospital · Beijing, Beijing Municipality · NCT07371923

• Sonrotoclax and Zanubrutinib With CAR-T in Mantle Cell Lymphoma

  This trial tests whether adding two oral drugs, sonrotoclax and zanubrutinib, to standard CAR-T therapy helps people with mantle cell lymphoma who have relapsed or are refractory after prior treatment.

  Recruiting at 5 sites Phase 2 Canadian Cancer Trials Group · Calgary, Alberta and 4 other locations · NCT07341191

• Adding a targeted cancer drug to standard therapy for untreated CLL/SLL

  This trial tests whether adding sonrotoclax to zanubrutinib helps people with untreated CLL/SLL live longer without the disease getting worse.

  Recruiting at 259 sites Phase 3 Alliance for Clinical Trials in Oncology · Birmingham, Alabama and 260 other locations · NCT07321652

• Zanubrutinib plus obinutuzumab and lenalidomide for first-line follicular lymphoma

  This trial tests whether the combination of zanubrutinib, obinutuzumab, and lenalidomide is safe and effective as a chemotherapy-free first treatment for adults with untreated follicular lymphoma.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT07299149

• Sonrotoclax plus zanubrutinib versus venetoclax plus acalabrutinib for adults with untreated CLL

  This tests whether a fixed-duration combination of sonrotoclax plus zanubrutinib works as well as or better than venetoclax plus acalabrutinib for adults with previously untreated CLL who need treatment.

  Recruiting at 114 sites Phase 3 BeOne Medicines · Duarte, California and 114 other locations · NCT07277231

• Zanubrutinib plus rituximab for secondary HLH linked to B‑cell lymphoma

  This test tries zanubrutinib together with rituximab (plus short steroids and ruxolitinib, with emapalumab if needed) to treat people who have secondary HLH caused by B‑cell lymphoma.

  Recruiting Phase 4 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07270835

• Obinutuzumab plus zanubrutinib and lenalidomide as first treatment for mantle cell lymphoma

  This trial will test whether a combination of obinutuzumab, zanubrutinib, and lenalidomide (with CAR‑T offered for high‑risk patients) works as a first‑line option for people newly diagnosed with mantle cell lymphoma.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT07261163

• Zanubrutinib plus rituximab as first-line treatment for marginal zone lymphoma

  This tests whether combining zanubrutinib and rituximab is effective and safe as first-line treatment for people with CD20-positive marginal zone lymphoma who have not received prior systemic therapy.

  Recruiting Henan Cancer Hospital · Zhengzhou, Henan · NCT07233720

• ZGR: zanubrutinib plus obinutuzumab and lenalidomide for newly diagnosed splenic B‑cell lymphoma with prominent nucleoli

  This trial tries the ZGR combination (zanubrutinib, obinutuzumab, and lenalidomide) as first‑line treatment for people with newly diagnosed SBLPN to see if it is effective and well tolerated.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07165769

• Fixed-duration zanubrutinib plus bendamustine and obinutuzumab for newly diagnosed advanced follicular lymphoma

  This tests a six-cycle combination of zanubrutinib, bendamustine, and obinutuzumab for adults with newly diagnosed advanced-stage follicular lymphoma.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07126678

• Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL

  A group of elderly patients with newly diagnosed diffuse large B-cell lymphoma will try a lighter chemotherapy approach using three targeted drugs to see if it works and is safe.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07012980

• ZR-MTX combo for newly diagnosed primary intraocular lymphoma

  This trial tests a Rituximab, Zanubrutinib, and methotrexate cocktail plus intravitreal methotrexate in people newly diagnosed with primary intraocular lymphoma to see if it can extend the time before the disease progresses.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06973811

• Zanubrutinib with G-CVP for untreated Follicular Lymphoma

  This study is testing if a new combination of zanubrutinib, obinutuzumab, and chemotherapy can help people with untreated follicular lymphoma feel better and stay healthy.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06959732

• Zanubrutinib plus sonrotoclax for relapsed or refractory B‑cell non‑Hodgkin lymphoma in underrepresented racial and ethnic groups

  This phase 1 trial tests whether combining zanubrutinib and sonrotoclax can help adults from underrepresented racial and ethnic groups whose B‑cell non‑Hodgkin lymphoma has returned or not responded to prior treatment.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06859008

• Bendamustine–Rituximab–Cytarabine plus Zanubrutinib induction followed by zanubrutinib/rituximab with or without sonrotoclax maintenance for newly diagnosed mantle cell lymphoma

  This trial tests whether giving zanubrutinib with a bendamustine‑rituximab‑cytarabine induction and then continuing zanubrutinib with rituximab, with or without sonrotoclax, helps people with newly diagnosed mantle cell lymphoma stay in remission longer.

  Recruiting at 4 sites Phase 2 Dana-Farber Cancer Institute · Phoenix, Arizona and 6 other locations · NCT06854003

• Zanubrutinib, obinutuzumab, and sonrotoclax for newly diagnosed CLL or SLL

  This trial tests whether the three‑drug combination of zanubrutinib, obinutuzumab, and sonrotoclax can produce undetectable measurable residual disease (uMRD) in people with previously untreated CLL or SLL.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT06849713

• Zanubrutinib with R-CHOP for DLBCL that has MYD88, CD79B, NOTCH1 changes, or is CD5+

  This study will try adding zanubrutinib to standard R-CHOP chemotherapy for adults with DLBCL who have an MYD88 L265P, CD79B, or NOTCH1 truncation mutation, or who are CD5+ by IHC.

  Recruiting Phase 2 Virginia Commonwealth University · Richmond, Virginia · NCT06846463

• Combination treatment for chronic lymphocytic leukemia and lymphoma

  This study is testing a new combination treatment with sonrotoclax and either zanubrutinib or rituximab to see if it can help patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT06839053

• Assessing the effectiveness and safety of zanubrutinib for marginal zone lymphoma patients in Italy

  This study is trying to see how well and safely zanubrutinib works for people in Italy with relapsed or hard-to-treat marginal zone lymphoma who have already received treatment.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Alessandria, Alessandria and 14 other locations · NCT06823960

• Treatment of Chronic Lymphocytic Leukaemia with Pirtobrutinib after Zanubrutinib

  This study is testing if the drug pirtobrutinib can help people with chronic lymphocytic leukaemia who didn’t respond to or relapsed after treatment with zanubrutinib.

  Recruiting Phase 2 Peter MacCallum Cancer Centre, Australia · Melbourne, Victoria and 2 other locations · NCT06812715

• Comparing sonrotoclax plus zanubrutinib to placebo plus zanubrutinib for relapsed mantle cell lymphoma

  This study is testing if adding sonrotoclax to zanubrutinib can help adults with relapsed mantle cell lymphoma feel better compared to just taking zanubrutinib with a placebo.

  Recruiting at 95 sites Phase 3 BeOne Medicines · Birmingham, Alabama and 144 other locations · NCT06742996

• Zanubrutinib with odronextamab for Richter's transformation

  This phase I test will see if combining zanubrutinib with odronextamab helps adults whose chronic lymphocytic leukemia has transformed into aggressive lymphoma (Richter's transformation).

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06735664

• Zanubrutinib combined with chemotherapy for patients with secondary CNS lymphoma

  This study is testing if a new combination of medications, including Zanubrutinib and chemotherapy, can help people with secondary Central Nervous System lymphoma feel better and improve their health.

  Recruiting Phase 1 University of Miami · Miami, Florida · NCT06730542

• Combination treatment for relapsed or refractory follicular lymphoma

  This study is testing a new combination of three medications to see if it can help people with relapsed or refractory follicular lymphoma feel better.

  Recruiting at 3 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT06563596

• Combining two drugs for patients with relapsed marginal zone lymphoma

  This study is testing a combination of two drugs, mosunetuzumab and zanubrutinib, to see if they can help people with relapsed marginal zone lymphoma feel better and improve their chances of recovery.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06563505

• Zanubrutinib with bendamustine and rituximab for untreated Waldenström macroglobulinemia

  This treatment will try zanubrutinib together with bendamustine and rituximab to see if it produces deep responses in people with untreated Waldenström macroglobulinemia.

  Recruiting at 5 sites Phase 2 Massachusetts General Hospital · Denver, Colorado and 4 other locations · NCT06561347

• Evaluating Glofitamab with Venetoclax and Zanubrutinib for high-risk Mantle-cell Lymphoma

  This study is testing a new combination of treatments for people with high-risk Mantle-cell Lymphoma to see if it helps them better than current options.

  Recruiting at 16 sites Phase 2 The Lymphoma Academic Research Organisation · Bruges and 15 other locations · NCT06558604

• Treatment for relapsed or refractory diffuse large B-cell lymphoma using a combination of drugs

  This study is testing a new combination of drugs to see if it can help people aged 18 to 75 with relapsed or refractory diffuse large B-cell lymphoma feel better and improve their chances of recovery.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hanzhou, Zhejiang · NCT06554600

• Combining Zanubrutinib and Obinutuzumab for Treating Newly Diagnosed Follicular Lymphoma

  This study is testing a new combination of two medications, Zanubrutinib and Obinutuzumab, to see if they can help people with newly diagnosed follicular lymphoma feel better and stay healthy.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06553352

• Combining zanubrutinib and obinutuzumab for untreated chronic lymphocytic leukemia or small lymphocytic lymphoma

  This study is testing if combining two medications, zanubrutinib and obinutuzumab, can help people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma achieve better treatment results.

  Recruiting at 19 sites Phase 2 PETHEMA Foundation · Alicante and 18 other locations · NCT06544785

• Comparing Pola-ZR2 and ZR2 for treating elderly patients with diffuse large B-cell lymphoma

  This study is testing if adding a new drug called polatuzumab vedotin to a standard treatment helps older patients with diffuse large B-cell lymphoma feel better and improve their outcomes.

  Recruiting Phase 3 Ruijin Hospital · Shanghai · NCT06522555

• Using zanubrutinib and lenalidomide for maintenance in lymphoma patients

  This study is testing whether the combination of zanubrutinib and lenalidomide can help people with diffuse large B-cell lymphoma stay in remission after chemotherapy.

  Recruiting Phase 2 Navy General Hospital, Beijing · Beijing, Beijing Municipality · NCT06503263

• Combining three medications for untreated follicular lymphoma

  This study is testing a new combination of three medications to see if they can effectively treat people with untreated follicular lymphoma without using traditional chemotherapy.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT06471738

• Combination treatment for untreated Mantle Cell Lymphoma patients

  This study is testing a new combination treatment without chemotherapy for people with untreated Mantle Cell Lymphoma to see if it can improve their health and survival.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT06463691

• GFH009 combined with Zanubrutinib for treating relapsed DLBCL

  This study is testing if a new treatment combining GFH009 and Zanubrutinib can help people with relapsed or hard-to-treat diffuse large B-cell lymphoma feel better.

  Recruiting at 2 sites Phase 1/2 Genfleet Therapeutics (Shanghai) Inc. · Nanning and 1 other locations · NCT06375733

• Combining rituximab and zanubrutinib for treating indolent B-cell lymphomas

  This study is testing if combining two medications, rituximab and zanubrutinib, can help people with untreated indolent B-cell lymphomas feel better and improve their treatment outcomes.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT06350318

• Using Zanubrutinib to maintain remission in patients with Mantle Cell Lymphoma

  This study is testing if Zanubrutinib can help people with mantle cell lymphoma stay in remission after their initial treatment.

  Recruiting at 2 sites Phase 2 Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT06341556

• Evaluating Zanubrutinib and Tislelizumab for Progressive Lymphoma After CAR-T Therapy

  This study is testing whether a combination of zanubrutinib and tislelizumab can help people with large B-cell lymphoma who have not responded well after CAR-T therapy.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT06167785

• Combining Zanubrutinib with Bendamustine and Rituximab for Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma

  This study is testing if combining a new drug called Zanubrutinib with two other treatments can help older patients with newly diagnosed mantle cell lymphoma feel better and improve their health.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT06136351

• Combining Zanubrutinib and Tafasitamab for Mantle Cell Lymphoma

  This study is testing the best dose of a new combination treatment with Zanubrutinib and Tafasitamab to see if it helps people with mantle cell lymphoma manage their disease better.

  Recruiting Phase 1/2 University of Miami · Miami, Florida · NCT06029309

• Zanubrutinib combined with R-CHOP for treating newly diagnosed DLBCL with p53 expression

  This study is testing if a new combination of zanubrutinib and R-CHOP can help people with newly diagnosed diffuse large B-cell lymphoma who have high levels of p53 protein.

  Recruiting Phase 2 Huazhong University of Science and Technology · Wuhan, Hubei · NCT06005870

• Comparing continuous and intermittent treatment with zanubrutinib for older patients with mantle cell lymphoma

  This study tests whether older patients with mantle cell lymphoma do better with continuous or intermittent treatment using zanubrutinib after they have achieved complete remission with rituximab.

  Recruiting at 233 sites Phase 3 Alliance for Clinical Trials in Oncology · Little Rock, Arkansas and 241 other locations · NCT05976763

• Combining zanubrutinib and CAR T-cell therapy for treating Richter's syndrome

  This study is testing if combining zanubrutinib with CAR T-cell therapy can help people with Richter's syndrome, which is when chronic lymphocytic leukemia turns into a more aggressive lymphoma.

  Recruiting at 3 sites Phase 2 Ohio State University Comprehensive Cancer Center · New York, New York and 2 other locations · NCT05873712

• Combining zanubrutinib and pemetrexed for treating relapsed or refractory CNS lymphomas

  This study is testing if combining two medications, zanubrutinib and pemetrexed, can help people with relapsed or stubborn central nervous system lymphomas feel better and live longer.

  Recruiting Phase 2 Baptist Health South Florida · Miami, Florida · NCT05681195

• Evaluating zanubrutinib for treating Waldenström Macroglobulinemia

  This study is testing how well zanubrutinib works and how safe it is for people with Waldenström macroglobulinemia, especially those with certain genetic traits and from different backgrounds.

  Recruiting at 6 sites BeOne Medicines · Huntsville, Alabama and 7 other locations · NCT05640102

• Combining Zanubrutinib and Rituximab for Indolent Mantle Cell Lymphoma

  This study is testing if a new combination of two medications, zanubrutinib and rituximab, can help people with indolent mantle cell lymphoma who haven't been treated before.

  Recruiting at 13 sites Phase 2 University College, London · Derby and 12 other locations · NCT05635162

• Treatment with Mosunetuzumab for newly diagnosed Follicular Lymphoma

  This study is testing if a new treatment called mosunetuzumab can help people who have just been diagnosed with follicular lymphoma feel better before they start other treatments.

  Recruiting at 9 sites Phase 2 Memorial Sloan Kettering Cancer Center · Washington D.C., District of Columbia and 8 other locations · NCT05389293

• Evaluating zanubrutinib treatment in patients with certain blood cancers

  This study is trying to see how well zanubrutinib works and how it affects the lives of adults with certain blood cancers like Waldenström's Macroglobulinemia and Chronic Lymphocytic Leukemia.

  Recruiting at 2 sites iOMEDICO AG · Salzburg and 1 other locations · NCT05326308

• Using zanubrutinib to treat immune thrombocytopenia

  This study tests if zanubrutinib can help people with immune thrombocytopenia who haven't had success with other treatments.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT05214391

• Using zanubrutinib to treat antiphospholipid syndrome with low platelet counts

  This study is testing if zanubrutinib can help people with antiphospholipid syndrome and low platelet counts who haven't found relief with other treatments.

  Recruiting at 2 sites Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT05199909

• Combination of zanubrutinib and venetoclax for treating chronic lymphocytic leukemia

  This study is testing if combining the drugs zanubrutinib and venetoclax can help adults with chronic lymphocytic leukemia who have already been treated feel better and manage their disease.

  Recruiting at 4 sites Phase 2 Dana-Farber Cancer Institute · Scarborough, Maine and 3 other locations · NCT05168930

• Comparing venetoclax and rituximab to ibrutinib and rituximab for treating Waldenstrom's macroglobulinemia

  This study is testing whether a new combination of venetoclax and rituximab works better than the standard treatment of ibrutinib and rituximab for people with Waldenstrom's macroglobulinemia who haven't been treated before.

  Recruiting at 106 sites Phase 2 National Cancer Institute (NCI) · Tucson, Arizona and 149 other locations · NCT04840602

• Combining zanubrutinib and tislelizumab for treating Richter Transformation

  This study is testing a new combination of two drugs, zanubrutinib and tislelizumab, to see if they can help people with Richter Transformation, a serious complication of chronic lymphocytic leukemia, when other treatments haven't worked.

  Recruiting at 10 sites Phase 2 German CLL Study Group · Vienna and 10 other locations · NCT04271956

Quick answers

How many clinical trials of Zanubrutinib are recruiting right now?

60, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 24 countries. The most sites are in China (29 trials), United States (23 trials), Germany (4 trials), Italy (4 trials), Spain (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 44, Phase 3: 5, Phase 1: 3, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →